Validation Data Gallery
Tested Applications
| Positive WB detected in | A549 cells, A431 cells, T-47D cells, PC-3 cells, HeLa cells, HepG2 cells, BxPC-3 cells |
| Positive IHC detected in | human lung cancer tissue, human ovary tumor tissue, human kidney tissue, human pancreas tissue, human breast cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF-P detected in | human prostate cancer tissue |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:10000-1:40000 |
| Immunohistochemistry (IHC) | IHC : 1:500-1:2000 |
| Immunofluorescence (IF)-P | IF-P : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 3 publications below |
| IHC | See 11 publications below |
| IF | See 11 publications below |
Product Information
66483-1-Ig targets Cytokeratin 7 in WB, IHC, IF-P, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse |
| Host / Isotype | Mouse / IgG2a |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag7895 Product name: Recombinant human CK7 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-351 aa of BC002700 Sequence: MSIHFSSPVFTSRSAAFSGRGAQVRLSSARPGGLGSSSLYGLGASRPRVAVRSAYGGPVGAGIREVTINQSLLAPLRLDADPSLQRVRQEESEQIKTLNNKFASFIDKVRFLEQQNKLLETKWTLLQEQKSAKSSRLPDIFEAQIAGLRGQLEALQVDGGRLEAELRSMQDVVEDFKNKYEDEINRRTAAENEFVVLKKDVDAAYMSKVELEAKVDALNDEINFLRTLNETELTELQSQISDTSVVLSMDNSRSLDLDGIIAEVKAQYEEMAKCSRAEAEAWYQTKFETLQAQAGKHGDDLRNTRNEISEMNRAIQRLQAEIDNIKNQRAKLEAAIAEAEERGELALKDAR 相同性解析による交差性が予測される生物種 |
| Full Name | keratin 7 |
| Calculated molecular weight | 469 aa, 51 kDa |
| Observed molecular weight | 51 kDa |
| GenBank accession number | BC002700 |
| Gene Symbol | Cytokeratin 7 |
| Gene ID (NCBI) | 3855 |
| RRID | AB_2881849 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P08729 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Keratins are a large family of proteins that form the intermediate filament cytoskeleton of epithelial cells, which are classified into two major sequence types. Type I keratins are a group of acidic intermediate filament proteins, including K9-K23, and the hair keratins Ha1-Ha8. Type II keratins are the basic or neutral courterparts to the acidic type I keratins, including K1-K8, and the hair keratins, Hb1-Hb6. KRT7, also named as cytokeratin 7, is one member of type II basic cytokeratin. It is specifically expressed in the simple epithelia lining the cavities of the internal organs and in the gland ducts and blood vessels, and their neoplasms. KRT7 is marker of epithelial tissues, but not present in carcinomas of stratified squamous cell origin.This antibody is specifically against KRT7.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for Cytokeratin 7 antibody 66483-1-Ig | Download protocol |
| IHC protocol for Cytokeratin 7 antibody 66483-1-Ig | Download protocol |
| WB protocol for Cytokeratin 7 antibody 66483-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Drug Resist Updat Targeting the USP5-HSPB1 axis overcomes ferroptosis resistance in intrahepatic cholangiocarcinoma. | ||
Nat Commun Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma | ||
Nat Commun Enrichment of decidual CD11c + CD8 + T cells with altered immune function in early pregnancy loss | ||
J Exp Clin Cancer Res IKBKE downregulation increases chemosensitivity through pyroptosis mediated by the caspase-3/GSDME pathway in pancreatic cancer. | ||
EBioMedicine Significance of integrated clinical and proteomic characteristics analysis for pathogenesis and management of Crohn's disease with concomitant psoriasis. | ||
Adv Healthc Mater In Situ Synthesis of Glycosaminoglycan-Mimicking Coatings Driven by Local Pathological Microenvironment: Boosting Bladder Mucosal Regeneration and Barrier Function. |